Trial Profile

A phase 3 trial of 67Cu SAR bisPSMA

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 67Cu SAR bisPSMA-Clarity Pharmaceuticals (Primary)
Indications Prostate cancer
Focus Diagnostic use; Registrational; Therapeutic Use

Most Recent Events

03 Feb 2026 New trial record
15 Jan 2026 The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com